OneSource Specialty Pharma Limited has unveiled a leadership reshuffle, elevating Preeti Kalra from the HR function to Senior Management Personnel, while Ravi Kumar has stepped down from his global head duties. The changes take effect on July 24, 2026, marking a notable shift in the company’s senior leadership as it navigates its next phase of growth.
Kalra arrives at a pivotal moment for the company’s people strategy. An HR leader with more than 25 years of experience spanning biopharma, global development, public services, insurance, GCC and IT, she has held executive roles across organizations including Stelis Biopharma, Biocon Biologics, the Bill & Melinda Gates Foundation, Serco and Ernst & Young. Her track record centers on talent management, leadership development, organizational transformation and driving culture and effectiveness—capabilities the company now leans on to build high-performing teams across its global footprint.
Ravi Kumar’s resignation from the post of Global Head – Injectables and Head of Corporate Strategy, Portfolio & SPO is described by the company as effective July 24, 2026, citing personal reasons. Kumar’s departure closes a chapter in a leadership block that bridged injectables operations with strategic portfolio oversight, and the company has shared the resignation letter as part of its official records.
Together, the moves underscore OneSource’s focus on strengthening its leadership engine—especially in HR and strategic oversight—while continuing to push forward with its growth agenda. The transition reflects a broader push to align executive leadership with the company’s ongoing evolution since its rebranding from Stelis Biopharma and its pursuit of complex biologics and specialty programs across multiple regions.